Gaetano Zaccara1, Fabio Giovannelli2,3, Filippo Sean Giorgi4, Valentina Franco5, Sara Gasparini6, Umberto Benedetto7. 1. Department of Medicine, Unit of Neurology, Florence Health Authority, Florence, Italy. 2. Department of Medicine, Unit of Neurology, Florence Health Authority, Florence, Italy. fabio.giovannelli@unifi.it. 3. Department of Neuroscience, Psychology, Pharmacology and Child Health (NEUROFARBA), University of Florence, Florence, Italy. fabio.giovannelli@unifi.it. 4. Section of Neurology, Pisa University Hospital, Pisa, Italy. 5. Department of Internal Medicine and Therapeutics, Division of Clinical and Experimental Pharmacology, University of Pavia, Pavia, Italy. 6. Department of Medical and Surgical Sciences, Magna Graecia University, Catanzaro, Italy. 7. School of Clinical Science, Bristol Heart Institute, University of Bristol, Bristol, UK.
Abstract
OBJECTIVE: The objective of this study was to perform a comparative assessment of tolerability of all licensed new antiepileptic drugs (AEDs) through a network meta-analysis (NMA) including all placebo-controlled double-blind clinical trials (RCTs) in all conditions in which these drugs have been tested. METHODS: NMA with a frequentist approach was used to compare proportions of patients withdrawing because of adverse events (AEs). Analyses were conducted for all therapeutic doses pooled and specifically for high therapeutic doses. Patients treated with non-therapeutic doses of each drug were excluded. RESULTS: A total of 195 RCTs were included in the current analysis, comprising a total of 28,013 patients treated with AEDs and 17,908 patients treated with placebo. RCTs included in the analysis were 8 for brivaracetam; 5 for eslicarbazepine; 22 for gabapentin; 7 for lacosamide; 14 for levetiracetam; 14 for lamotrigine; 6 for oxcarbazepine; 9 for perampanel; 50 for pregabalin; 5 for tiagabine; 36 for topiramate; 7 for zonisamide; 4 for gabapentin-extended formulation (ER); 2 each for levetiracetam-ER, lamotrigine-ER, and topiramate-ER; and 1 each for oxcarbazepine-ER and pregabalin-ER. Brivaracetam, gabapentin, gabapentin-ER, and levetiracetam had a significantly lower withdrawal rate compared to several other AEDs, while eslicarbazepine, lacosamide, oxcarbazepine, and topiramate had a higher withdrawal rate. Perampanel, lamotrigine, pregabalin, tiagabine, and zonisamide showed an intermediate pattern of tolerability. Additional analysis has been conducted through selection of highly recommended doses for each drug. This analysis has roughly confirmed results of head to head comparisons of the all-dose analysis, with some exceptions. A further analysis has been conducted after exclusion of RCTs in which patients were allocated to the therapeutic dose of the experimental drug without titration, and it failed to show clinically important differences. SIGNIFICANCE: Relevant differences in short-term tolerability of AEDs have been observed between AEDs. Brivaracetam, gabapentin, and levetiracetam show the best tolerability profile while other AEDs are at higher risk for intolerable adverse effects.
OBJECTIVE: The objective of this study was to perform a comparative assessment of tolerability of all licensed new antiepileptic drugs (AEDs) through a network meta-analysis (NMA) including all placebo-controlled double-blind clinical trials (RCTs) in all conditions in which these drugs have been tested. METHODS: NMA with a frequentist approach was used to compare proportions of patients withdrawing because of adverse events (AEs). Analyses were conducted for all therapeutic doses pooled and specifically for high therapeutic doses. Patients treated with non-therapeutic doses of each drug were excluded. RESULTS: A total of 195 RCTs were included in the current analysis, comprising a total of 28,013 patients treated with AEDs and 17,908 patients treated with placebo. RCTs included in the analysis were 8 for brivaracetam; 5 for eslicarbazepine; 22 for gabapentin; 7 for lacosamide; 14 for levetiracetam; 14 for lamotrigine; 6 for oxcarbazepine; 9 for perampanel; 50 for pregabalin; 5 for tiagabine; 36 for topiramate; 7 for zonisamide; 4 for gabapentin-extended formulation (ER); 2 each for levetiracetam-ER, lamotrigine-ER, and topiramate-ER; and 1 each for oxcarbazepine-ER and pregabalin-ER. Brivaracetam, gabapentin, gabapentin-ER, and levetiracetam had a significantly lower withdrawal rate compared to several other AEDs, while eslicarbazepine, lacosamide, oxcarbazepine, and topiramate had a higher withdrawal rate. Perampanel, lamotrigine, pregabalin, tiagabine, and zonisamide showed an intermediate pattern of tolerability. Additional analysis has been conducted through selection of highly recommended doses for each drug. This analysis has roughly confirmed results of head to head comparisons of the all-dose analysis, with some exceptions. A further analysis has been conducted after exclusion of RCTs in which patients were allocated to the therapeutic dose of the experimental drug without titration, and it failed to show clinically important differences. SIGNIFICANCE: Relevant differences in short-term tolerability of AEDs have been observed between AEDs. Brivaracetam, gabapentin, and levetiracetam show the best tolerability profile while other AEDs are at higher risk for intolerable adverse effects.
Authors: John-Kenneth Sake; David Hebert; Jouko Isojärvi; Pamela Doty; Marc De Backer; Kendra Davies; Andrea Eggert-Formella; James Zackheim Journal: CNS Drugs Date: 2010-12 Impact factor: 5.749
Authors: Shannon Cope; Jie Zhang; Stephen Saletan; Brielan Smiechowski; Jeroen P Jansen; Peter Schmid Journal: BMC Med Date: 2014-06-05 Impact factor: 8.775
Authors: Alyn H Morice; Eva Millqvist; Kristina Bieksiene; Surinder S Birring; Peter Dicpinigaitis; Christian Domingo Ribas; Michele Hilton Boon; Ahmad Kantar; Kefang Lai; Lorcan McGarvey; David Rigau; Imran Satia; Jacky Smith; Woo-Jung Song; Thomy Tonia; Jan W K van den Berg; Mirjam J G van Manen; Angela Zacharasiewicz Journal: Eur Respir J Date: 2020-01-02 Impact factor: 16.671
Authors: K S Frederiksen; C Cooper; G B Frisoni; L Frölich; J Georges; M G Kramberger; C Nilsson; P Passmore; L Mantoan Ritter; D Religa; R Schmidt; E Stefanova; A Verdelho; M Vandenbulcke; B Winblad; G Waldemar Journal: Eur J Neurol Date: 2020-07-26 Impact factor: 6.089
Authors: Areti Angeliki Veroniki; Patricia Rios; Elise Cogo; Sharon E Straus; Yaron Finkelstein; Ryan Kealey; Emily Reynen; Charlene Soobiah; Kednapa Thavorn; Brian Hutton; Brenda R Hemmelgarn; Fatemeh Yazdi; Jennifer D'Souza; Heather MacDonald; Andrea C Tricco Journal: BMJ Open Date: 2017-07-20 Impact factor: 2.692